Complete blood count (CBC)-derived indices have been proposed as reliable inflammatory biomarkers to predict outcomes in the context of coronary artery disease. These indices have yet to be thoroughly validated in patients with intermediate coronary stenosis. Our study included 1527 patients only with intermediate coronary stenosis. The examined variables were neutrophil–lymphocyte ratio (NLR), derived NLR, monocyte–lymphocyte ratio (MLR), platelet–lymphocyte ratio (PLR), systemic immune inflammation index (SII), system inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI). The primary endpoint was the composite of major adverse cardiovascular events (MACEs), including all-cause death, non-fatal myocardial infarction, and unplanned revascularization. Over a follow-up of 6.11 (5.73–6.55) years, MACEs occurred in 189 patients. Receiver operator characteristic curve analysis showed that SIRI outperformed other indices with the most significant area under the curve. In the multivariable analysis, SIRI (hazard ratio [HR] 1.588, 95% confidence interval [CI] 1.138–2.212) and AISI (HR 1.673, 95% CI 1.217–2.300) were the most important prognostic factors among all the indices. The discrimination ability of each index was strengthened in patients with less burden of modifiable cardiovascular risk factors. SIRI also exhibited the best incremental value beyond the traditional cardiovascular risk model.
RossR. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115-126.
2.
PearsonTAMensahGAAlexanderRWCenters for Disease Control and PreventionAmerican Heart Association, et al.. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation. 2003;107:499-511.
3.
Group L-TIwPiIDLS. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
4.
Group HPSC. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7.
5.
DownsJRClearfieldMWeisS, et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air force/Texas coronary atherosclerosis prevention study. JAMA. 1998;279:1615-1622.
6.
Cholesterol Treatment Trialists’ CTT CollaborationBaigentCBlackwellLEmbersonJ, et al.Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
7.
BaigentCKeechAKearneyPMCholesterol Treatment Trialists’ CTT Collaborators, et al.. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
8.
CannonCPBlazingMAGiuglianoRP, et al.Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397.
9.
KauraAHartleyAPanoulasV, et al.Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: a cohort study. PLoS Med. 2022;19:e1003911.
10.
FanolaCLMorrowDACannonCP, et al.Interleukin‐6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID‐TIMI 52 (stabilization of plaque using Darapladib—thrombolysis in myocardial infarction 52) Trial. J Am Heart Assoc. 2017;6:e005637.
11.
ChaudhuryANoiretLHigginsJM. White blood cell population dynamics for risk stratification of acute coronary syndrome. Proc Natl Acad Sci USA. 2017;114:12344-12349.
12.
GuastiLDentaliFCastiglioniL, et al.Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A systematic review on more than 34,000 subjects. Thromb Haemostasis. 2011;106:591-599.
13.
ArbelYFinkelsteinAHalkinA, et al.Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis. 2012;225:456-460.
14.
UrbanowiczTOlasińska-WiśniewskaAMichalakM, et al.The prognostic significance of Neutrophil to Lymphocyte Ratio (NLR), Monocyte to Lymphocyte Ratio (MLR) and Platelet to Lymphocyte Ratio (PLR) on long-term survival in Off-Pump Coronary Artery Bypass Grafting (OPCAB) procedures. Biology. 2021;11:34.
15.
LiQMaXShaoQ, et al.Prognostic impact of multiple lymphocyte-based inflammatory indices in acute coronary syndrome patients. Front Cardiovasc Med. 2022;9:811790.
16.
TobisJAzarbalBSlavinL. Assessment of intermediate severity coronary lesions in the catheterization laboratory. J Am Coll Cardiol. 2007;49:839-848.
17.
ManoharanGNtalianisAMullerO, et al.Severity of coronary arterial stenoses responsible for acute coronary syndromes. Am J Cardiol. 2009;103:1183-1188.
18.
TebaldiMBiscagliaSFineschiM, et al.Evolving routine standards in invasive hemodynamic assessment of coronary stenosis: the nationwide Italian SICI-GISE cross-sectional ERIS study. JACC Cardiovasc Interv. 2018;11:1482-1491.
19.
PatelPRaoRSethiPMukherjeeAVaradarajanPPaiRG. Functional assessment of coronary artery lesions-old and new kids on the block. Int J Angiol. 2021;30:40-47.
20.
LeveyASStevensLASchmidCHCKD-EPI Chronic Kidney Disease Epidemiology Collaboration, et al.. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
21.
BäckMYurdagulAJTabasIÖörniKKovanenPT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16:389-406.
22.
Silvestre-RoigCBrasterQOrtega-GomezASoehnleinO. Neutrophils as regulators of cardiovascular inflammation. Nat Rev Cardiol. 2020;17:327-340.
23.
WoollardKJGeissmannF. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 2010;7:77-86.
24.
MauersbergerCHinterdoblerJSchunkertHKesslerTSagerHB. Where the action is-leukocyte recruitment in atherosclerosis. Front Cardiovasc Med. 2022;8:813-984.
25.
CarboneFNencioniAMachFVuilleumierNMontecuccoF. Pathophysiological role of neutrophils in acute myocardial infarction. Thromb Haemostasis. 2013;110:501-514.
26.
PaulGKSenBBariMA, et al.Correlation of platelet count and acute ST-elevation in myocardial infarction. Mymensingh Med J. 2010;19:469-473.
27.
SchulzCMassbergS. Atherosclerosis—multiple pathways to lesional macrophages. Sci Transl Med. 2014;6:239ps2.
28.
MontecuccoFLiberaleLBonaventuraAVecchièADallegriFCarboneF. The role of inflammation in cardiovascular outcome. Curr Atherosclerosis Rep. 2017;19:11.
29.
BadimonLPadróTVilahurG. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur Heart J Acute Cardiovasc Care. 2012;1:60-74.
30.
LandryPPlanteIOuelletDLPerronMPRousseauGProvostP. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol. 2009;16:961-966.
31.
EdelsteinLCMcKenzieSEShawCHolinstatMAKunapuliSPBrayPF. MicroRNAs in platelet production and activation. Blood. 2013;11:340-350.
32.
SaigusaRWinkelsHLeyK. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol. 2020;17:387-401.
33.
TabasILichtmanAH. Monocyte-Macrophages and T Cells in atherosclerosis. Immunity. 2017;47:621-634.
34.
OnsrudMThorsbyE. Influence of in vivo hydrocortisone on some human blood lymphocyte subpopulations: I. Effect on natural killer cell activity. Scand J Immunol. 1981;13:573-579.
HofmannUBeyersdorfNWeiratherJ, et al.Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation. 2012;125:1652-1663.
37.
RupareliaNGodecJLeeR, et al.Acute myocardial infarction activates distinct inflammation and proliferation pathways in circulating monocytes, prior to recruitment, and identified through conserved transcriptional responses in mice and humans. Eur Heart J. 2015;36:1923-1934.
38.
DuttaPNahrendorfM. Monocytes in myocardial infarction. Arterioscler Thromb Vasc Biol. 2015;35:1066-1070.
39.
WangYPengCChengZ, et al.The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: a systematic review and meta-analysis. Int J Surg. 2018;55:73-80.
40.
QianBZhengYJiaHZhengXGaoRLiW. Neutrophil-lymphocyte ratio as a predictive marker for postoperative infectious complications: a systematic review and meta-analysis. Heliyon. 2023;9:e15586.
41.
FahmiRMRamadanBMSalahHElsaidAFShehtaN. Neutrophil-lymphocyte ratio as a marker for disability and activity in multiple sclerosis. Mult Scler Relat Disord. 2021;51:102921.
42.
DongC-HWangZ-MChenS-Y. Neutrophil to lymphocyte ratio predict mortality and major adverse cardiac events in acute coronary syndrome: a systematic review and meta-analysis. Clin Biochem. 2018;52:131-136.
43.
FanZLiYJiHJianX. Prognostic utility of the combination of monocyte-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with NSTEMI after primary percutaneous coronary intervention: a retrospective cohort study. BMJ Open. 2018;8:e023459.
44.
JiHLiYFanZ, et al.Monocyte/lymphocyte ratio predicts the severity of coronary artery disease: a syntax score assessment. BMC Cardiovasc Disord. 2017;17:90.
45.
ChenHLiMLiuLDangXZhuDTianG. Monocyte/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients with non-ST-elevation myocardial infarction. Medicine. 2019;98:e16267.
46.
LiLHChenCTChangYCChenYJLeeIHHowCK. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune inflammation index in acute ischemic stroke: a STROBE-compliant retrospective study. Medicine (Baltim). 2021;100:e26354.
47.
MaimaitiALiYWangYT,et al.Association of platelet-to-lymphocyte count ratio with myocardial reperfusion and major adverse events in patients with acute myocardial infarction: a two-centre retrospective cohort study. BMJ Open. 2019;9:e025628.
48.
ZhouDFanYWanZ, et al.Platelet-to-lymphocyte ratio improves the predictive power of GRACE risk score for long-term cardiovascular events in patients with acute coronary syndrome. Cardiology. 2016;134:39-46.
49.
ZhouDWangGFanYWanZLiuX. Platelet to lymphocyte ratio is associated with the severity of coronary artery disease and clinical outcomes of percutaneous coronary intervention in the Chinese Han population. Exp Ther Med. 2017;13:731-738.
50.
OylumluMYıldızAOylumluM, et al.Platelet-to-lymphocyte ratio is a predictor of in-hospital mortality patients with acute coronary syndrome. Anatol J Cardiol. 2015;15:277-283.
51.
ErdoğanMErdölMAOzturkSDurmazT. Systemic immune-inflammation index is a novel marker to predict functionally significant coronary artery stenosis. Biomarkers Med. 2020;14:1553-1561.
52.
LiuYYeTChenL, et al.Systemic immune-inflammation index predicts the severity of coronary stenosis in patients with coronary heart disease. Coron Artery Dis. 2021;32:715-720.
53.
SuGZhangYXiaoRZhangTGongB. Systemic immuneinflammation index as a promising predictor of mortality in patients with acute coronary syndrome: a real-world study. J Int Med Res. 2021;49:3000605211016274.
54.
HanKShiDYangL, et al.Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Ann Med. 2022;54:1667-1677.
55.
AmbroseJAWintersSLAroraRR, et al.Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol. 1986;7:472-478.
56.
Alsheikh-AliAAKitsiosGDBalkEMLauJIpS. The vulnerable atherosclerotic plaque: scope of the literature. Ann Intern Med. 2010;153:387-395.
57.
NiiokaHKumeTKuboT, et al.Automated diagnosis of optical coherence tomography imaging on plaque vulnerability and its relation to clinical outcomes in coronary artery disease. Sci Rep. 2022;12:14067.
58.
NaghaviMLibbyPFalkE, et al.From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664-1672.
59.
AguirreADArbab-ZadehASoedaTFusterVJangIK. Optical coherence tomography of plaque vulnerability and rupture: JACC focus seminar part 1/3. J Am Coll Cardiol. 2021;78:1257-1265.
60.
JiangJZengHZhuoY, et al.Association of neutrophil to lymphocyte ratio with plaque rupture in acute coronary syndrome patients with only intermediate coronary artery lesions assessed by optical coherence tomography. Front Cardiovasc Med. 2022;9:770760.
61.
HoganMBergerJS. Heparin-Induced Thrombocytopenia (HIT): review of incidence, diagnosis, and management. Vasc Med. 2020;25:160-173.
62.
SharmaAFergusonCBaineyKR. Thrombocytopenia in acute coronary syndromes: etiologies and proposed management. Can J Cardiol. 2015;31:809-811.
63.
SellengKSellengSRaschkeR, et al.Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin. Am J Hematol. 2005;78:188-192.
64.
ThompsonCBDiazDDQuinnPGLapinsMKurtzSRValeriCR. The role of anticoagulation in the measurement of platelet volumes. Am J Clin Pathol. 1983;80:327-332.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
